Abstract
BackgroundInjectable cabotegravir (CAB)/rilpivirine (RPV) (CAR) is the first long-acting (LA) antiretroviral (ART) regimen approved for virologically suppressed people living with HIV (PLWH). Despite the available clinical trial results, the causes...
Paper version not known (
Free)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have